ClinicalTrials.gg
CompletedNCT02340234Updated Oct 2, 2017

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Completed at 74 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
17th of 24
212 · median 252
Started
2015
with 1 other
Phase 2
3 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
2 of 24
Hoffmann-La Roche

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 17th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical corticosteroids (TCS). The study includes a screening visit, a 2-week run-in period, a 12-week blinded treatment period, and an 8-week safety follow-up period. Following screening visit, eligible participants will enter in run-in period (Days - 14 to - 1) during which a protocol-specified topical therapy regimen will be initiated. At the end of the run-in period, participants who have: 1) demonstrated compliance with the protocol-specified TCS regimen, and 2) who continue to fulfill the eligibility criteria will be randomized.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD diagnosed by the Hanifin/Rajka criteria and that has been present for at least 1 year at screening
  • Moderate to severe AD as graded by the Rajka/Langeland criteria at screening
  • History of inadequate response to a >/= 1 month (within the 3 months prior to the screening visit) treatment regimen of at least daily TCS and regular emollient for treatment of AD
  • EASI score >/= 14 at screening and end of the run-in period
  • IGA score >/= 3 (5-point scale) at screening and end of the run-in period
  • AD involvement of >/= 10% BSA at screening
  • Pruritus VAS score >/= 3 at screening

Exclusion criteria

Exclusion Criteria:

  • Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Use of an agent within 4 weeks prior to screening or within 5 half-lives of the investigational agent, whichever is longer
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Use of any complementary, alternative, or homeopathic medicines including, but not limited to, phytotherapies, traditional or non-traditional herbal medications, essential fatty acids, or acupuncture within 7 days prior to the run-in period or need for such medications during the study
  • Evidence of other skin conditions; including, but not limited to, T-cell lymphoma or allergic contact dermatitis
  • Evidence of, or ongoing treatment (including topical antibiotics) for active skin infection at screening
  • Other recent infections meeting protocol criteria
  • Active tuberculosis requiring treatment within the 12 months prior to Visit 1
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • Known immunodeficiency, including (HIV) infection
  • Use of a topical calcineurin inhibitor (TCI) at the time of screening, unless the participant is willing to stop TCI use during the study (including the run-in period) and, in the investigator's opinion, it is safe to do so
  • abnormality on screening (ECG) or laboratory tests that, in the opinion of the investigator, may pose an additional risk in administering study drug or TCS to the participant
  • Known current or current evaluation for a potential malignancy, including basal or squamous cell carcinoma of the skin or carcinoma in situ
  • History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (actual)

Study arms

  • Experimental
    Lebrikizumab 250 mg Single Dose + TCS Cream

    Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

    Drug: Lebrikizumab · Drug: Placebo · Drug: TCS Cream

  • Experimental
    Lebrikizumab 125 mg Single Dose + TCS Cream

    Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

    Drug: Lebrikizumab · Drug: Placebo · Drug: TCS Cream

  • Experimental
    Lebrikizumab 125 mg Q4W + TCS Cream

    Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

    Drug: Lebrikizumab · Drug: TCS Cream

  • Placebo comparator
    Placebo Q4W + TCS Cream

    Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

    Drug: Placebo · Drug: TCS Cream

Interventions

  • Lebrikizumab will be administered SC as per the schedule specified in the respective arms.

  • DrugPlacebo

    Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.

  • DrugTCS Cream

    TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-50) at Week 12

    Time frame: Week 12

Secondary outcomes

  1. Percent Change From Baseline in EASI Score at Week 12

    Time frame: Baseline, Week 12

  2. Absolute Change From Baseline in EASI Score at Week 12

    Time frame: Baseline, Week 12

  3. Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score (EASI-75) at Week 12

    Time frame: Week 12

  4. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 12

    Time frame: Week 12

  5. Percentage of Participants With a Greater Than or Equal to (>/=) 2 Point Reduction From Baseline in IGA at Week 12

    Time frame: Week 12

  6. Absolute Change From Baseline in IGA at Week 12

    Time frame: Baseline, Week 12

  7. Percentage of Participants Achieving an Investigator Global Signs Assessment (IGSA) Score of 0 or 1 at Week 12

    Time frame: Week 12

  8. Percentage of Participants with a >/=2 Point Reduction From Baseline in IGSA at Week 12

    Time frame: Week 12

  9. Absolute Change From Baseline in IGSA at Week 12

    Time frame: Baseline, Week 12

  10. Percent Change From baseline in Severity Scoring of Atopic Dermatitis (SCORAD) at Week 12

    Time frame: Baseline, Week 12

  11. Absolute Change From baseline in SCORAD at Week 12

    Time frame: Baseline, Week 12

  12. Percentage of Participants With a 50% or 75% Reduction From Baseline in SCORAD-50/75 at Week 12

    Time frame: Week 12

  13. Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16

    Time frame: Weeks 12, 16

  14. Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16 and 20

    Time frame: Weeks 12, 16, 20

  15. Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16

    Time frame: Weeks 12, 16

  16. Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16 and 20

    Time frame: Weeks 12, 16, 20

  17. Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16

    Time frame: Weeks 12, 16

  18. Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16 and 20

    Time frame: Weeks 12, 16, 20

  19. Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16

    Time frame: Weeks 12, 16

  20. Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16 and 20

    Time frame: Weeks 12, 16, 20

  21. Percent Change From Baseline in Total % Body Surface Area (BSA) Affected At Week 12

    Time frame: Baseline, Week 12

  22. Absolute Change From Baseline in Pruritus as Measured by the Pruritus Visual Analog Scale (VAS) at Week 12

    Time frame: Baseline, Week 12

  23. Percent Change From Baseline in Pruritus as Measured by the Pruritus VAS at Week 12

    Time frame: Baseline, Week 12

  24. Absolute Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12

    Time frame: Baseline, Week 12

  25. Percent Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12

    Time frame: Baseline, Week 12

  26. Total Use (Grams) of TCS From Baseline to Week 12

    Time frame: From Baseline to Week 12

  27. Total Use (Grams) of TCS From Week 12 to End of Study or Early Termination

    Time frame: From Week 12 to end of study or early termination (up to approximately 20 weeks)

  28. Number of Disease Flares From Baseline to Week 12

    Time frame: From Baseline to Week 12

  29. Change in AD Symptoms From Baseline to Week 12, as Assessed by the Atopic Dermatitis Symptom Diary (ADSD)

    Time frame: Baseline, Week 12

  30. Change in AD-Specific HealthRelated Quality of Life (QoL) From Baseline to Week 12, as Assessed by the Atopic Dermatitis Impact Questionnaire (ADIQ)

    Time frame: Baseline, Week 12

  31. Change in Health-Related QoL From Baseline to Week 12, as Measured by the Dermatology Life Quality Index (DLQI)

    Time frame: Baseline, Week 12

  32. Percentage of Participants With Treatment-Emergent Adverse Events (AEs)

    Time frame: From start of run-in period (Day -14) until study completion (up to approximately 20 Weeks)

  33. Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Lebrikizumab

    Time frame: Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)

  34. Percentage of Participants With ATA to Phospholipase B-Like 2 (PLBL2) Protein

    Time frame: Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)

  35. Percentage of Participants With Disease Rebound

    Time frame: From Week 12 up to approximately 20 weeks

  36. Maximum Serum Concentration (Cmax) of Lebrikizumab

    Time frame: After first dose of lebrikizumab at Week 1

  37. Time to Reach Cmax (Tmax) of Lebrikizumab

    Time frame: After first dose of lebrikizumab at Week 1

  38. Minimum Serum Concentration (Cmin) of Lebrikizumab

    Time frame: Pre-dose at Weeks 4, 8, 12

  39. Elimination Half-Life (t1/2) of Lebrikizumab

    Time frame: Pre-dose on Days 1, 8, 29, 43, 57, 85, 113, 141, study discontinuation visit (up to Day 141)

07

Study locations

74 sites
  • Dermatology Research Associate
    Los Angeles, California 90045, United States
  • UCSD Division of Dermatology
    San Diego, California 92122, United States
  • Univ of Calif-San Francisco
    San Francisco, California 94115, United States
  • University of Colorado; Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Northwestern University Feinberg School Of Medicine
    Chicago, Illinois 60611, United States
  • University of Iowa Healthcare; Dermatology
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Washington University; Dermatology
    Saint Louis, Missouri 63110, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Oregon Health & Science University; Department of Dermatology
    Portland, Oregon 97239-4501, United States
  • University of Texas Medical School-Houston
    Houston, Texas 77030, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Clinical Research Inc.
    Norfolk, Virginia 23502, United States
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • Skin & Cancer Foundation
    Carlton, Victoria 3053, Australia
  • Royal Melbourne Hospital; Dermatology Department
    Parkville, Victoria 3050, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Guildford Dermatology Specialists
    Surrey, British Columbia V3R 6A7, Canada
  • Dr. Melinda Gooderham Medicine Professional Corporation
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research Inc.
    Windsor, Ontario N8W 1E6, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec L2K 4L5, Canada
  • Faculty Hospital; Department of Dermatology
    Plzen, 305 99, Czechia
  • Charles University School of Medicine; Deptartment of Dermatology
    Prague 10, 100 34, Czechia
  • Masarykova nemocnice o.z; kozni oddeleni
    Usti nad Labem, 401 13, Czechia
  • Helsinki University Central Hospital; Skin & Allergy Hospital
    Helsinki, 00029, Finland
  • Tampere University Hospital; Dermatology and allergology
    Tampere, 33520, Finland
  • Turku Central University Hospital; Dermatology and allergology
    Turku, 20250, Finland
  • Hopital Saint Andre CHU De Bordeaux; Dermatologie
    Bordeaux, 33075, France
  • Hopital du Bocage; Dermatologie
    Dijon, 21079, France
  • Hopital Hotel Dieu Et Hme; Clinique Dermatologique
    Nantes, 44093, France
  • Hopital l Archet 2; Ginestriere, Service de; Dermatologie
    Nice cedex 3, 06200, France
  • Centre Hospitalier Lyon Sud; Dermatologie
    Pierre Benite, 69495, France
  • Charite Mitte; Klinik fur Dermatologie
    Berlin, 10117, Germany
  • Universitätsklinik Bonn
    Bonn, 53127, Germany
  • Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie
    Frankfurt, 60590, Germany
  • SRH Wald-Klinikum Gera GmbH; Hautkrankheiten und Allergologie
    Gera, 07548, Germany
  • UKSH Kiel; Klinik für Dermatologie, Venerologie und Allergologie
    Kiel, 24105, Germany
  • Universitätsklinikum Mainz
    Mainz, 55131, Germany
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • ChungAng University Hospital
    Seoul, 06973, Korea, Republic of
  • Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU University Medical Center
    Amsterdam, 1100 DD, Netherlands
  • University Medical Center Groningen; Department of Dermatology
    Groningen, 9700RB, Netherlands
  • UMC Utrecht; Dermatology
    Utrecht, 3584 CX, Netherlands
  • Uniwersyteckie Centeum Kliniczne GUMed; Klinika Dermatologii, Wenerologii i Alergologii
    Gdańsk, 80-402, Poland
  • DERMED Centrum Medyczne; Sp zoo
    Lodz, 90-265, Poland
  • Laser Clinic
    Szczecin, 70-322, Poland
  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o
    Tarnow, 33-100, Poland
  • dermMedica sp.z o.o.
    Wroclaw, 51-318, Poland
  • Clinica Universitaria de Navarra; Servicio de Dermatologia
    Pamplona, Navarra 31008, Spain
  • Hospital de la Santa Creu i Sant Pau; Servicio de Dermatologia
    Barcelona, 08025, Spain
  • Hospital Universitario La Princesa, Servicio dermatologia
    Madrid, 28006, Spain
  • HUGregorio Marañón, Servicio de dermatología
    Madrid, 28007, Spain
  • Hospital Ramon y Cajal; servicio dermatologia
    Madrid, 28034, Spain
  • Hospital Universitario La Paz; Servicio de dermatologia
    Madrid, 28046, Spain
  • Hospital General Universitario de Valencia; servicio de dermatología
    Valencia, 46014, Spain
  • Inselspital Bern; Dermatologie
    Bern, 3000, Switzerland
  • CHUV; Dermatologie
    Lausanne, 1011, Switzerland
  • Universitätsspital Zürich; Dermatologische Klinik
    Zürich, 8091, Switzerland
  • Chang Gung Medical Foundation;Kaohsiung Branch; Department of Dermatology
    Kaohsiung, 83301, Taiwan
  • National Cheng-Kung University Hospital; Department of Dermatology
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital; Department of Dermatology
    Taipei, 10048, Taiwan
  • Russells Hall Hospital
    Dudley, DY1 2HQ, United Kingdom
  • Guys and St Thomas NHS Foundation Trust, Guys Hospital; Skin Therapy Research Unit
    London, SE1 9RT, United Kingdom
  • Newcastle University & The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LJ, United Kingdom
  • Poole Hospital
    Poole, BH15 2JB, United Kingdom
  • Salford Royal NHS Foundation Trust
    Salford, M6 8HD, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2015
First posted
Jan 16, 2015
Start
May 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Oct 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02340234
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 16, 2015
Start date
May 2015
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Oct 2, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion